Sun Pharma inks pact with Takeda to introduce gastrointestinal drug in India

Sun Pharmaceutical Industries announced a licensing deal with Takeda Pharmaceutical to market Vonoprazan, a novel gastrointestinal drug, in India. The agreement allows Sun Pharma to commercialize 10 mg and 20 mg tablets of Vonoprazan, an innovative treatment for acid peptic disorders, under a non-exclusive patent license.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/X84RfQ2
via IFTTT